These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1171 related items for PubMed ID: 12174922

  • 1. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K, TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [Abstract] [Full Text] [Related]

  • 2. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
    Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K.
    J Clin Oncol; 2007 Jun 20; 25(18):2509-15. PubMed ID: 17577027
    [Abstract] [Full Text] [Related]

  • 3. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
    Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL.
    J Clin Oncol; 2006 Nov 01; 24(31):4956-62. PubMed ID: 17075113
    [Abstract] [Full Text] [Related]

  • 4. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group.
    de Haes H, Olschewski M, Kaufmann M, Schumacher M, Jonat W, Sauerbrei W, Zoladex Early Breast Cancer Research Association Trialists Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4510-6. PubMed ID: 14610048
    [Abstract] [Full Text] [Related]

  • 5. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M.
    Cancer J Sci Am; 1999 Dec 15; 5(2):101-11. PubMed ID: 10198732
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B, Mouridsen HT, Jensen MB.
    Acta Oncol; 2008 Dec 15; 47(4):662-71. PubMed ID: 18465334
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, Coates AS, International Breast Cancer Study Group Trial VIII.
    J Clin Oncol; 2007 Jan 20; 25(3):263-70. PubMed ID: 17159194
    [Abstract] [Full Text] [Related]

  • 8. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B, Jeong JH, Anderson S, Wolmark N.
    J Natl Cancer Inst; 2004 Dec 15; 96(24):1823-31. PubMed ID: 15601638
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L, Cancer and Leukemia Group B.
    J Clin Oncol; 2003 May 01; 21(9):1825-35. PubMed ID: 12721260
    [Abstract] [Full Text] [Related]

  • 11. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD.
    J Clin Oncol; 2005 Sep 01; 23(25):5973-82. PubMed ID: 16087950
    [Abstract] [Full Text] [Related]

  • 12. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 13. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
    von Minckwitz G, Graf E, Geberth M, Eiermann W, Jonat W, Conrad B, Brunnert K, Gerber B, Vescia S, Wollert J, Kaufmann M.
    Eur J Cancer; 2006 Aug 20; 42(12):1780-8. PubMed ID: 16765589
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5166-70. PubMed ID: 16051958
    [Abstract] [Full Text] [Related]

  • 15. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group.
    J Natl Cancer Inst; 2007 Apr 04; 99(7):506-15. PubMed ID: 17405995
    [Abstract] [Full Text] [Related]

  • 16. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M, German Adjuvant Breast Cancer Group.
    J Clin Oncol; 2005 Nov 01; 23(31):7842-8. PubMed ID: 16258087
    [Abstract] [Full Text] [Related]

  • 17. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P.
    Clin Cancer Res; 1995 Feb 01; 1(2):189-98. PubMed ID: 9815973
    [Abstract] [Full Text] [Related]

  • 18. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2008 Apr 01; 14(7):2082-7. PubMed ID: 18381948
    [Abstract] [Full Text] [Related]

  • 19. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K.
    N Engl J Med; 1997 Oct 02; 337(14):949-55. PubMed ID: 9395428
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial.
    Groenvold M, Fayers PM, Petersen MA, Mouridsen HT.
    Breast Cancer Res Treat; 2006 Aug 02; 98(3):275-84. PubMed ID: 16541325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.